An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
RenovoRx to Participate in Upcoming October 2022 Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical firm specializing in localized treatment of solid tumors, is set to participate in two investor conferences in October 2022. CEO Shaun Bagai will present at the ROTH Inaugural Healthcare Opportunities Conference on October 6 and the LD Micro Main Event XV from October 25-27. He will discuss the company's therapy platform and address the challenges of treating pancreatic tumors. RenovoRx's lead product, RenovoGem, is in a Phase 3 trial targeting unresectable locally advanced pancreatic cancer.
Positive
None.
Negative
None.
LOS ALTOS, Calif.--(BUSINESS WIRE)--
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform, today announced management’s participation in two upcoming investor conferences this month. Conferences include ROTH Inaugural Healthcare Opportunities, October 6th, and LD Micro Main Event XV, October 25th-27th.
Shaun Bagai, RenovoRx’s CEO, will provide a corporate update during his presentations. He will also discuss current available treatment options for pancreatic tumors, why they can fall short of providing an effective solution for treating this deadly disease, and how RenovoRx’s therapy platform re-envisions the treatment of pancreatic and other difficult-to-treat cancers. During the Conferences, Shaun will participate in one-on-one meetings with the investment community. Attendees include public companies, and institutional and private investors. To schedule a meeting, please reach out to your conference representative or send an email to KCSA Strategic Communications at RenovoRx@KCSA.com.
ROTH Inaugural Healthcare Opportunities Conference Format and Dates: In-person, October 6, 2022 Location:Club Quarters Hotel Grand Central, New York, New York Presenter:Shaun Bagai, CEO
Presentation Date and Time:Thursday, October 6th at 12:40 p.m. ET Register:https://www.meetmax.com/sched/event_88609/conference_home.html
LD Micro Main Event XV
Format and Dates: In-person, October 25-27th, 2022
Location:Luxe Sunset Boulevard Hotel, Los Angeles, California Presenter:Shaun Bagai, CEO
Presentation Date and Time:Wednesday, October 26th at 12:30 p.m. PT Register:https://me22.sequireevents.com/
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.
RenovoRx’s patent portfolio for its therapy platform and product candidates includes seven U.S. patents, one European patent and several additional patents pending in the US, EU and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.
RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its RenovoTAMP technology.
Company Contact:
RenovoRx, Inc. Shaun R. Bagai, CEO
James Ahlers, CFO
Investor Contact:
KCSA Strategic Communications Valter Pinto or Jack Perkins T:212-896-1254
renovorx@kcsa.com
Source: RenovoRx, Inc.
FAQ
What are the upcoming investor conferences for RenovoRx (RNXT) in October 2022?
RenovoRx will participate in the ROTH Inaugural Healthcare Opportunities Conference on October 6 and the LD Micro Main Event XV from October 25-27.
Who will present on behalf of RenovoRx at the investor conferences?
CEO Shaun Bagai will present at both investor conferences.
What will Shaun Bagai discuss during the conferences?
He will provide a corporate update and discuss current treatment options for pancreatic tumors and how RenovoRx's platform offers a new approach.
What is the focus of RenovoRx's therapy platform?
RenovoRx's platform focuses on localized treatment of difficult-to-treat solid tumors using the RenovoTAMP technology.
What is RenovoGem and its current trial status?
RenovoGem is RenovoRx's lead product candidate, currently being studied in the Phase 3 TIGeR-PaC trial for unresectable locally advanced pancreatic cancer.
